Clinical trial

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer

NCT03081234

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2018-03-31

PhasePHASE3

Study timeline

Study start (estimated)2018-03-31Date precision: day

Registry last updated2018-03-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

RibociclibDRUG · verified · RxNorm: ribociclib

PlaceboDRUG

Adjuvant endocrine therapyDRUG

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03081234 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.